Zacks: Brokerages Set $7.00 Price Target for Motus GI Holdings (MOTS)

Motus GI Holdings (NASDAQ:MOTS) has earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.

Brokerages have set a 12 month consensus price objective of $7.00 for the company and are anticipating that the company will post ($0.29) earnings per share for the current quarter, according to Zacks. Zacks has also given Motus GI an industry rank of 103 out of 265 based on the ratings given to related companies.

Get Motus GI alerts:

MOTS has been the subject of several research analyst reports. Piper Jaffray initiated coverage on Motus GI in a research report on Sunday, March 11th. They set an “overweight” rating and a $7.00 target price for the company. Oppenheimer initiated coverage on Motus GI in a research report on Monday, March 12th. They set an “outperform” rating and a $7.00 target price for the company. Finally, ValuEngine downgraded Motus GI from a “hold” rating to a “sell” rating in a research report on Monday, April 2nd.

NASDAQ:MOTS opened at $5.34 on Thursday. Motus GI has a twelve month low of $3.75 and a twelve month high of $7.85.

An institutional investor recently bought a new position in Motus GI stock. Hilltop Holdings Inc. acquired a new stake in Motus GI Holdings (NASDAQ:MOTS) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 112,100 shares of the company’s stock, valued at approximately $502,000. Hilltop Holdings Inc. owned approximately 0.72% of Motus GI at the end of the most recent reporting period. Institutional investors and hedge funds own 0.01% of the company’s stock.

Motus GI Company Profile

Motus GI Holdings, Inc, a medical technology company, focuses on the development and commercialization of the Pure-Vu System. Its Pure-Vu System is designed to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.

Get a free copy of the Zacks research report on Motus GI (MOTS)

For more information about research offerings from Zacks Investment Research, visit

Leave a Reply

Your email address will not be published.